GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Degree of Operating Leverage

FGEN (FibroGen) Degree of Operating Leverage : 0.33 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. FibroGen's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.33. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for FibroGen's Degree of Operating Leverage or its related term are showing as below:

FGEN's Degree of Operating Leverage is ranked worse than
58.64% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs FGEN: 0.33

FibroGen Degree of Operating Leverage Historical Data

The historical data trend for FibroGen's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Degree of Operating Leverage Chart

FibroGen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.88 1.64 -0.04 -0.11 0.48

FibroGen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.49 0.61 0.48 0.33

Competitive Comparison of FibroGen's Degree of Operating Leverage

For the Biotechnology subindustry, FibroGen's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where FibroGen's Degree of Operating Leverage falls into.


;
;

FibroGen Degree of Operating Leverage Calculation

FibroGen's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -129.854 (Mar. 2025) / -287.02 (Mar. 2024) - 1 )/( -23.543 (Mar. 2025) / 36.006 (Mar. 2024) - 1 )
=-0.5476/-1.6539
=0.33***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


FibroGen  (NAS:FGEN) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


FibroGen Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of FibroGen's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen Business Description

Industry
Traded in Other Exchanges
Address
350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Executives
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158